These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26165039)

  • 21. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthracycline war: no victor yet.
    Young P
    J Natl Cancer Inst; 2009 Sep; 101(17):1171-3. PubMed ID: 19706625
    [No Abstract]   [Full Text] [Related]  

  • 23. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    De Maeyer L; Van Limbergen E; De Nys K; Moerman P; Pochet N; Hendrickx W; Wildiers H; Paridaens R; Smeets A; Christiaens MR; Vergote I; Leunen K; Amant F; Neven P
    J Clin Oncol; 2008 Jan; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
    [No Abstract]   [Full Text] [Related]  

  • 24. Disease related indicators for a proper choice of adjuvant treatments.
    Hayes DF
    Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 29. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailored targeted therapy for all: a realistic and worthwhile objective against.
    Pritchard KI
    Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S8. PubMed ID: 20030883
    [No Abstract]   [Full Text] [Related]  

  • 31. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
    Zhang B
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):241-4. PubMed ID: 21575491
    [No Abstract]   [Full Text] [Related]  

  • 34. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
    Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
    Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy.
    Asaga S; Kinoshita T; Hojo T; Suzuki J; Jimbo K; Tsuda H
    Clin Breast Cancer; 2013 Feb; 13(1):40-6. PubMed ID: 23103363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
    Metzger-Filho O; de Azambuja E
    J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective.
    Gupta S; Zhang J; Jerusalem G
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):929-40. PubMed ID: 25130198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.